anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine.SUBSTANCE: invention refers to medicine, cardiology, biophysics, diagnostics of non-infectious diseases by means of electrocardiosignal treatment (ECT). Disclosed is a method in which ECT matrix information analysis involves continuous simultaneous removal of 600 electrocardiocycles in 1st, 2nd and 3rd standard Einthoven leads or Goldbergar unipolar reinforced leads from extremities. Duration (Dn) of the QRS-ventricular complexes and the ratio Rnand the subsequent time interval (Tn) representing arctg are determined. αn, which conditionally reflects the phase deviations (Fn+1) of each subsequent cardiac cycle relative to the previous one (Fn). Measurements are carried out with increase in quantisation frequency up to 10 kHz and more. Array of registered ECS is arranged with the help of "window". In structuring array for the pacemaker via said "window" encoded characters of the Latin alphabet, each fragment structured ECT. Thus, the code of each ECT structural unit in the form of a linear matrix includes three cardiac cycles, which is represented by a sum of four coding symbols. Spatial matrixed codogram is formed, which is a set of linear matrices obtained during coding, which reflect simultaneously three cardiac cycles. Method includes calculating and ranking them according to frequency of occurrence, comparing with standard spatial matrices rates and diseases, which are obtained by the same method and include matrices of only 100 % of occurrence among healthy people or patients with certain specific diseases. Conclusion on the norm or disease is carried out in the presence of a corresponding reference matrix in the linear and spatial matrix code of the examined individual.EFFECT: method provides more accurate diagnosis of diseases of internal organs of non-infectious nature at any stage of their development with achievement of completeness and objectivity of information analysis of ECT, including all types of modulation of parameters of pulsed signals: amplitude-pulse, interval-pulse or frequency-pulse, long-pulse and phase-pulse modulation.1 cl, 2 dwg, 2 ex, 1 tbl
PURPOSE: Artificial eye users (AEUs) can experience a negative impact on psychological and emotional wellbeing, including reduced social functioning, which may be a consequence of living with one eye removed, and/or of having a prosthetic eye. This may have wider consequences for their families. We aimed to explore what it means to live with a prosthetic eye, for both AEUs and their families-and how any quality of life (QoL) issues impact on their day-to-day functioning.
METHODS: A subset of AEUs and their family members taking part in a feasibility randomised controlled trial comparing hand-painted to digitally printed artificial eyes were invited for semi-structured interviews. Transcripts were analysed using reflexive thematic analysis. Qualitative results related to trial participation are covered elsewhere. Here, we focus on QoL and day-to-day functioning.
RESULTS: Twelve AEUs (eight males) and five spouses (one male) who had worn artificial eyes for 2-65 years took part, and four themes were identified. (1) Impact on day-to-day life: AEUs and their spouses have to adapt to (partial) sight loss, reduced levels of confidence, and social withdrawal. (2) Impact on psychological and emotional wellbeing: distress among AEUs and their spouses can be severe and prolonged, highlight unmet support needs. (3) Challenges with treatment experiences: AEUs experienced negative impact of fragmentation of care and long waiting times. (4) Worries about the future: AEUs mentioned fragility of remaining sight, and concerns around potential need for further treatment.
CONCLUSION: Patients and their family members experience negative impact of being an AEU on their everyday lives and quality of life. There is a potential role for psychosocial support services in supporting AEUs and their families even long after eye loss.
In order to calibrate the differential pressure measurement to a geodetic height difference of (approximately) zero, the reference-location defining part (2) is led so close up to the blood pressure measuring device that, if a minimum distance between two points defined on the reference-location defining part (2) and on the blood-pressure measuring device (1), respectively, is fallen below, a calibration signal is triggered. A control device integrated into or connected to the blood-pressure measuring device (1) performs the calibration measurement as a reaction to the triggering signal. The triggering means are implemented as a reference-location-defining-part RFID tag (10) and an associated blood-pressure-measuring-device near-field communication reading device (11). If the near-field communication reading device (11) in the blood-pressure measuring device (1) detects the correctly coded RFID tag in the reference-location defining part (2), the near-field communication reading device triggers the calibration signal. The reference-location defining part (2), which is to be attached to the patient, is preferably designed, with associated increased requirements for sterility, as a disposable article. The reference-location defining part is connected to the blood-pressure measuring device by means of the tube connection (12) such that there is a continuous liquid column between a liquid reservoir (13) in the reference-location defining part (2) and a correction pressure sensor (14) in the blood-pressure measuring device (1).
The present invention relates to novel use of bacteriocin derived from Enterococcus faecalis SL-5. More particularly, the present invention relates to a composition for preventing and treating acne comprising a polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2, which is a bacteriocin derived from Enterococcus faecalis SL-5. Also, it relates to use of the bacteriocin for the manufacture of an agent for preventing or treating acne, and a method for preventing or treating acne comprising administering or applying the bacteriocin to subject in need thereof. The present invention provides a polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2 derived from Enterococcus faecalis SL-5, which shows excellent antibacterial activity against Propionibacterium acnes inducing acne. The inventive polypeptide can inhibit growth of Propionibacterium acnes by having excellent antibacterial activity against them inducing acne. Accordingly, the inventive polypeptide can be effectively used in preventing, treating and improving acne.
INTRODUCTION: Among the conditions underlying childhood daytime incontinence the most frequent is overactive bladder (OAB). Parasacral transcutaneous electrical nerve stimulation (parasacral TENS) is a promising therapy for OAB treatment in children; however, there is no standard treatment protocol.
OBJECTIVE: To evaluate the immediate and continued effects of parasacral TENS monotherapy in children with OAB.
STUDY DESIGN: 57 children at mean age 10.8 years diagnosed with OAB at a single centre were prospectively enrolled from 2013 to 2018. The inclusion criterion was typical OAB symptoms. The treatment results were evaluated based on objective measurements from bladder diaries, 48 h frequency/volume (48 h F/V) charts, and uroflowmetry. The parasacral TENS treatment lasted for 4 months, twice daily, with 1 h sessions. Results were evaluated at three time points: 2 months of therapy, 4 months (end of active therapy), and 10 months (6 months after cessation of therapy).
RESULTS: After 4 months of parasacral TENS treatment, the number of days with daytime incontinence decreased from 7.23 to 3.94/14 days (p < 0.05), nocturnal enuresis decreased from 6.81 to 3.77/14 days (p < 0.05), and urgency episodes from 7.36 to 3.58 in 14 days (p < 0.05). Treatment effects remained stable 6 months after therapy cessation regarding days with daytime incontinence (from 3.94 [immediately after treatment] to 3.28 in 14 days [6 months after treatment cessation]), nocturnal enuresis (from 3.77 to 2.91 in 14 days), and urgency episodes (from 3.58 to 2.12 in 14 days) (p < 0.05). Complete response after 6 months of therapy was observed in 32% of patients with daytime incontinence, 35% with nocturnal enuresis, and 50% with urgency episodes.
DISCUSSION: A recent systematic review of parasacral TENS in children with OAB included only two studies with a follow up of 6 months or longer after treatment cessation; therefore, little is known about the continued effects of parasacral TENS. High rates of complete symptom remission were reported in studies where only subjective symptoms were evaluated. Results of our study reveal that the positive effect of treatment persist. The strengths of the present study include its prospective design, large sample size, and uniform standard urotherapy performed prior to TENS.
CONCLUSIONS: The use of parasacral TENS in children with OAB is effective and results in a significant reduction in daytime incontinence, nocturnal enuresis, and urgency episodes. A longer treatment duration of 4 months leads to more improvement and the effects remain stable 6 months after treatment cessation.
The present invention relates to and dull-witted comprise prunus mume (sieb.) sieb.et zucc. (Prunus for preventing or treating? mume) (Fructus Mume (Fructus? Mume)) the compositions of extract, and prunus mume (sieb.) sieb.et zucc. extract of the present invention is improving space identity ability and is making the Hippocampal Injury normalization of being induced by chronic vascular brain injury (make ERK phosphorylation normalization in creation, increasing ChAT and also make NF-κ B normalization) aspect has remarkable effect, therefore the medicine for preventing or treat dementia disease can be advantageously used for, and be used as the functional health-care food preventing or alleviate the dementia disease (such as vascular dementia) with vascular brain injury.
INTRODUCTION: Urothelial bladder cancer is frequent and exhibits diverse prognoses influenced by molecular subtypes, urothelial subtype histology, and immune microenvironments. HLA-G, known for immune regulation, displays significant membranous expression in tumor tissues.
METHODS: We studied the protein expression of Human Leucocyte Antigen G (HLA-G) in 241 Muscle-Invasive Bladder Cancer (MIBC) patients, elucidating its potential clinical and biological significance. Protein expression levels were evaluated and correlated with molecular subtypes, histological characteristics, immune microenvironment markers, and survival outcomes.
RESULTS: High HLA-G expression associates with poor overall survival (OS) and diseasespecific survival (DSS), independent of clinicopathological parameters. HLA-G expression varies among molecular subtypes and Urothelial Subtype Histology, e.g., elevated expression levels in basal/squamous MIBC and those with sarcomatoid differentiation. Notably, HLA-G is increased in MIBC with an immune evasive microenvironment (high PD-L1 tumor cell expression, NK cell depletion, granzyme B (GZMB)/CD8 ratio reduction, MHC class I (MHCI) expression reduction) that are characterized by immunosuppressive features and poor prognosis. Furthermore, HLA-G correlates with elevated levels of other immune checkpoint proteins (TIGIT, LAG3, CTLA-4), indicating its role in immune evasion.
DISCUSSION: Our findings underscore HLA-G's role as a potential prognostic marker and interesting immunotherapeutic target in MIBC. Its impact on immune evasion mechanisms and broad expression, coupled with associations withpoor survival and distinct tumor phenotypes, positions HLA-G as a promising protein for further exploration in developing targeted immunotherapies for MIBC patients.
The efficacy of Effexor XR as a treatment for Panic Disorder (PD) was established in two double-blind, 12-week, multicenter, placebo-controlled studies in adult outpatients meeting DSM-IV criteria for PD, with or without agoraphobia. Patients received fixed doses of 75 or 150 mg per day in one study (study 1) and 75 or 225 mg per day in the other study (study 2).

Efficacy was assessed on the basis of outcomes in three variables: (1) percentage of patients free of full-symptom panic attacks on the Panic and Anticipatory Anxiety Scale (PAAS); (2) mean change from baseline to endpoint on the Panic Disorder Severity Scale (PDSS) total score; and (3) percentage of patients rated as responders (much improved or very much improved) on the Clinical Global Impressions (CGI) Improvement scale. In these two studies, Effexor XR was statistically significantly more effective than placebo (for each fixed dose) on all three endpoints, but a dose-response relationship was not clearly established.

Examination of subsets of the population studied did not reveal any differential responsiveness on the basis of gender. There was insufficient information to determine the effect of age or race on outcome in these studies.

In a longer term study (study 3), adult outpatients meeting DSM-IV criteria for PD who had responded during a 12-week open phase with Effexor XR (75 to 225 mg per day) were randomly assigned to continue the same Effexor XR dose (75, 150, or 225 mg) or switch to placebo for observation for relapse under double-blind conditions. Response during the open phase was defined as ≤ 1 full-symptom panic attack per week during the last 2 weeks of the open phase and a CGI Improvement score of 1 (very much improved) or 2 (much improved). Relapse during the double-blind phase was defined as having 2 or more full-symptom panic attacks per week for 2 consecutive weeks or having discontinued due to loss of effectiveness as determined by the investigators during the study. Randomized patients were in response status for a mean time of 34 days prior to being randomized. In the randomized phase following the 12-week open-label period, patients receiving continued Effexor XR experienced a statistically significantly longer time to relapse.
BACKGROUND: DNA methylation integrates environmental signals with transcriptional programs. COVID-19 infection induces changes in the host methylome. While post-acute sequelae of COVID-19 (PASC) is a long-term complication of acute illness, its association with DNA methylation is unknown. No universal blood marker of PASC, superseding single organ dysfunctions, has yet been identified.
METHODS: In this single centre prospective cohort study, PASC, post-COVID without PASC, and healthy participants were enrolled to investigate their symptoms association with peripheral blood DNA methylation data generated with state-of-the-art whole genome sequencing. PASC-induced quality-of-life deterioration was scored with a validated instrument, SF-36. Analyses were conducted to identify potential functional roles of differentially methylated loci, and machine learning algorithms were used to resolve PASC severity.
FINDINGS: 103 patients with PASC (22.3% male, 77.7% female), 15 patients with previous COVID-19 infection but no PASC (40.0% male, 60.0% female), and 27 healthy volunteers (48.1% male, 51.9% female) were enrolled. Whole genome methylation sequencing revealed 39 differentially methylated regions (DMRs) specific to PASC, each harbouring an average of 15 consecutive positions, that differentiate patients with PASC from the two control groups. Motif analyses of PASC-regulated DMRs identify binding domains for transcription factors regulating circadian rhythm and others. Some DMRs annotated to protein coding genes were associated with changes of RNA expression. Machine learning support vector algorithm and random forest hierarchical clustering reveal 28 unique differentially methylated positions (DMPs) in the genome discriminating patients with better and worse quality of life.
INTERPRETATION: Blood DNA methylation levels identify PASC, stratify PASC severity, and suggest that DNA motifs are targeted by circadian rhythm-regulating pathways in PASC.
FUNDING: This project has been funded by the following agencies: NIH-AI173035 (A. Jaitovich and R. Alisch); and NIH-AG066179 (R. Alisch).
PURPOSE:To provide a remedy for peptic ulcer containing tocopheryl retinoate, a hydroxypropylcellulose having low substitution degree and polyvinyl pyrrolidone as essential components. CONSTITUTION:The objective agent can be prepared by compounding 0.05-60wt.% of powdery tocopheryl retinoate adsorbed to silica having a diameter of <=3mum, 5-20wt.% of a hydroxypropylcellulose having low substitution degree, 2-15wt.% of a polyvinyl pyrrolidone having a molecular weight of 30,000-40,000 and, as necessary, a vehicle (e.g. corn starch) and/or a lubricant (e.g. magnesium stearate) and forming in the form of drug preparation by conventional method. An antioxidant such as ascorbic acid is preferably added to the mixture to prevent the oxidation of tocopheryl retinoate. The agent can be prepared in the form of powder, fine granule, granule, capsule, tablet. etc.
The present invention is based on our work with E-cadherin, including soluble portions of this integral membrane glycoprotein. The compositions of the present invention include therapeutically effective amounts of a first agent that targets epitopes within one or more of the EC2-EC5 subdomains of the ectodomain of E-cadherin (induing these domains in the shed sEcad fragment) and a second agent that inhibits one or more of: endothelial tube formation; angiogenesis; the human epidermal growth factor receptor family (i.e. HER1-4); an insulin-like growth factor 1 receptor (IGF-1R); any other receptor tyrosine kinase receptor family member; the P13K-MAPK pathway; and the P13K/Akt/mTOR pathway. The compositions can be used in the treatment of epithelial cancers, and may effectively inhibit cellular proliferation, migration, and/or invasiveness. Thus, the present compositions can be used to inhibit tumor growth and metastasis. The present compositions can be used in the treatment of "triple negative" breast cancer patients (in whom breast cancer cells test negative for estrogen receptors, progesterone receptors, and HER2), as well as HER2 -positive and other HER2 -negative tumors. In addition to therapeutic and prophylactic treatment methods, the invention features methods in which cancer is staged depending on the relative amounts of full-length (FL) E-cadherin and soluble E-cadherin (sEcad) and/or with another predictive biomarker for cancer. The greater the amount of sEcad relative to the amount of FL E-cadherin, the more advanced the cancer.
An implantable sustained-release microneedle patch and a preparation method therefor. The implantable sustained-release microneedle comprises a needle tip, a needle body, and a base. The needle tip comprises a needle tip center layer and a needle tip outer layer. The needle tip center layer is formed of a matrix comprising a biodegradable water-insoluble polymer material. The needle tip outer layer, the needle body and the base are formed of a matrix comprising a water-soluble polymer material. The microneedle patch comprises the microneedle, and absorbs moisture of skin when the microneedle acts on skin, so that the base and the needle body are quickly separated from the needle tip within 0.5-2h. After the base is removed, the needle tip will be left in skin, and the user does not need the patch sticking for a long time to ensure long-term release of a drug in the body.
This study was a Randomized control trial. Conducted in Railway General Hospital Rawalpindi from January 2019 to July 2019. 300 older adults were screened and 112 were selected on the basis of inclusion criteria. Subjects were randomly allocated to control and experimental group through toss and coin method, 56 being in each group. Control group subjects received balance and strengthening exercises 3 times in a week for 4 weeks. While experimental group participants received same balance and strengthening exercises with whole body vibration 3 times in a week for 4 weeks. Vibration exposure was given in 1-minute bouts, with rest period of one to two minutes between bouts, with the exposure whole body vibration for about four minutes on every session, Balance exercises included tandem walk 20 steps and single leg raise with weights 10 repetition.(8,9) Tools used in this study were Berg Balance scale a 14 item scale. The score of each item ranges from zero to four, zero being the last point and 4 being the highest point the total score for these 14 items were 56. If the score is between 41 to56 then it is considered normal if it is from 20 to 40 the risk of balance deficits are moderate but if the score comes below 19 then risk of fall enhances. Almost 10 to 15 minutes are required to perform this scale on an individual. Functional Independence Measure It consisted of eighteen item; for motor items score 13 and five for cogitation which includes communication and cognition, each of the value is scored on a 7-point scale. The third tool used in this study was Time Up and Go test asses the static and dynamic balance it requires the time taken by individual to raise from a chair walk three meters, turn around walk back and sit on the chair. Subjects in both groups were pre assessed using these three tools and after completion of four weeks subjects were reassessed and the difference of score was noted. Data of this study was analyzed by using SPSS software version 25.
Rationale: A long-term prospective natural history study in an unselected group of patients including clinical and functional outcome measures is lacking in both SELENON-related myopathy (SELENON-RM) and LAMA2-related muscular dystrophy (LAMA2-MD). Due to the promising ongoing preclinical trials, there is a high need to obtain natural history data in order to reach trial readiness for both diseases. With the extended LAST STRONG study, we aim to further analyze and expand our 1.5-year natural history data on SELENON-RM and LAMA2-MD to provide a detailed clinical description of the Dutch and Flemish cohort. This will enable a smooth transition towards implementation into clinical care and clinical trials that are expected to start within 5 years.

Objective: (1) To collect 3- and 5-year natural history data in patients with SELENON-RM and LAMA2-MD. (2) Implementation of natural history data collection into clinical care and international guidelines, and reach trial readiness.

Study design: This is an observational study. A variety of tests will be performed to get a full impression of the patient's abilities and disabilities (standard medical history, neurological examination, functional measurements, questionnaires, imaging, pulmonary assessment and accelerometry). The tests that the patient undergoes depend on the age/abilities/wishes. The tests are selected based on our previously performed 1.5-year natural history study in LAMA2-MD and SELENON-RM. Each participant will perform these measurements during the two scheduled visits at 3- and 5-year after the first visit during the LAST STRONG Study.

Risk and benefit assessment: This study does not concern any product (medicinal product, food product or medical device). There is a small risk for minor injury, e.g. when a participant falls. However since the investigators use all functional tests using movements to which most participants are familiar (i.e. walking, transfers, etc.), the participant will be able to estimate his/her own risk. The investigators don't include tests in which they push participants to their physical limits. the investigators conclude that this study has a negligible risk. A benefit includes the possibility for participants to get a detailed analysis on their own health. Additionally, participants will contribute to the design of future clinical trials on possible treatment options.